- Home
- GLSI vs INO Comparison
GLSI vs INO Comparison
Compare GLSI & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLSI | INO |
|---|---|---|
| Founded | 2006 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.9M | 116.1M |
| IPO Year | 2020 | 1998 |
Fundamental Metrics
Financial Performance| Metric | GLSI | INO |
|---|---|---|
| Price | $26.60 | $1.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $50.00 | $9.00 |
| AVG Volume (30 Days) | 758.8K | ★ 2.0M |
| Earning Date | 11-14-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $182,337.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $23,060.18 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.78 | $1.30 |
| 52 Week High | $32.91 | $2.98 |
Technical Indicators
Market Signals| Indicator | GLSI | INO |
|---|---|---|
| Relative Strength Index (RSI) | 66.68 | 35.49 |
| Support Level | $18.54 | $1.50 |
| Resistance Level | $32.91 | $1.70 |
| Average True Range (ATR) | 4.63 | 0.11 |
| MACD | 0.35 | -0.02 |
| Stochastic Oscillator | 56.09 | 8.89 |
Price Performance
Historical ComparisonAbout GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.